Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies
| Autor: | Yongcai Mao, Jane Xu, Josephine Cucchiaro, Stephen R. Marder, Robert Silva, Antony Loebel, Andrei Pikalov |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Exacerbation medicine.drug_class Atypical antipsychotic Placebo Lurasidone Hydrochloride 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine medicine Humans Psychiatry Randomized Controlled Trials as Topic Lurasidone Psychiatric Status Rating Scales Positive and Negative Syndrome Scale business.industry Repeated measures design Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Treatment Outcome Pooled analysis Schizophrenia Female Schizophrenic Psychology business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | European Psychiatry. 30:26-31 |
| ISSN: | 1778-3585 0924-9338 |
| Popis: | Objective:To evaluate the efficacy of lurasidone for schizophrenia using an established five-factor model of the Positive and Negative Syndrome Scale (PANSS).Methods:Patient-level data were pooled from five randomized, double-blind, placebo-controlled, 6-week studies of lurasidone (fixed doses, 40–160 mg/d) for patients with an acute exacerbation of schizophrenia. Changes in five established PANSS factors were assessed using mixed-model repeated measures analysis.Results:Compared with placebo (n = 496), lurasidone (n = 1029, dose groups pooled) significantly improved the PANSS total score at Week 6 (−22.6 vs. −12.8; P < 0.001; effect size, 0.45), as well as all factor scores (P < 0.001 for each): positive symptoms (−8.4 vs. −6.0; effect size, 0.43), negative symptoms (−5.2 vs. −3.3; effect size, 0.33), disorganized thought (−4.9 vs. −2.8; effect size, 0.42), hostility/excitement (−2.7 vs. −1.6; effect size, 0.31), and depression/anxiety (−3.2 vs. −2.3; effect size, 0.31). Separation from placebo occurred at Week 1 for the positive symptoms, disorganized thought, and hostility/excitement factors and at Week 2 for the other factors.Conclusions:In this pooled analysis of short-term studies in patients with acute schizophrenia, lurasidone demonstrated significant improvement for each of the five PANSS factor scores, indicating effectiveness across the spectrum of schizophrenia symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|